Adagene, Inc. (ADAG)
| Market Cap | 356.68M |
| Revenue (ttm) | 700,913 |
| Net Income (ttm) | -42.65M |
| Shares Out | 43.58M |
| EPS (ttm) | -2.50 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,154 |
| Open | 8.15 |
| Previous Close | 8.53 |
| Day's Range | 7.65 - 8.45 |
| 52-Week Range | 7.00 - 31.83 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 31.64 (+286.6%) |
| Earnings Date | n/a |
About ADAG
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its lead product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb for cancer treatment; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of variou...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Adagene stock is "Buy." The 12-month stock price forecast is 31.64, which is an increase of 286.56% from the latest price.
News
Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG10...
Clinical trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium Clinic...
Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Cand...
- Successful nomination of lead SAFEbody candidates triggers milestone payment -
Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a ...
- Posters presented at the 63 rd American Society of Hematology Annual Meeting -
Adagene's Posts Early Safety, Efficacy Data From Cold Tumors Trial
Adagene Inc (NASDAQ: ADAG) announced clinical data on ADG116, and ADG106, in two poster presentations at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021. ADG116 monothe...
Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pan...
Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab Additional highlights include pharmacodynami...
Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumor...
- Additional highlights include pharmacodynamic biomarker analyses from ongoing trial of anti-CD137 antibody, ADG106, in combination with anti-PD-1 toripalimab - - Additional highlights include pharmaco...
Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study
The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.
Adagene Shares Jump After FDA Signs Off ADG116/Keytruda Combo Therapy Trial In Solid Tumors
The FDA has cleared Adagene Inc's (NASDAQ: ADAG) Investigational New Drug (IND) application to proceed with a Phase 1b/2 trial of ADG116, in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrol...
Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination ...
ADG116-P001 trial being initiated at multiple sites with dosing to begin early 2022 ADG116-P001 trial being initiated at multiple sites with dosing to begin early 2022
Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congr...
SAN DIEGO and SUZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discover...
Adagene to Participate in Upcoming Investor & Industry Conferences in November
SAN DIEGO and SUZHOU, China, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discover...
Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology...
- Presentations demonstrate compelling preclinical differentiation of an anti-CD47 antibody and a CD20xCD3 bispecific T-cell engager, both leveraging SAFEbody ™ technology -
Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Sma...
- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium -
Adagene to Participate in the Jefferies Virtual China Biotech Summit
SAN FRANCISCO and SUZHOU, China, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the disc...
Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming...
Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates
- Established three clinical collaborations with Merck to conduct global combination trials with pembrolizumab for three clinical-stage oncology candidates -
Adagene Inks Third Cancer Trial Collaboration With Merck
Adagene Inc (NASDAQ: ADAG) has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The agreement includes an open-label, dose-escalation, and expansio...
Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combina...
Collaboration to evaluate NEObody™ product candidate, ADG106, in combination with KEYTRUDA® for patients with advanced or metastatic solid and/or hematological malignancies Collaboration to evaluate NEO...
Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory B...
- Global immuno-oncology experts bring decades of experience to advance company's transformative research and development pipeline - - Global immuno-oncology experts bring decades of experience to advan...
Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytruda In Solid Tumors
Adagene Inc (NASDAQ: ADAG) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). The agreement includes two clinical studies to evaluate Adagene's anti-C...
Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (AD...
Two global clinical studies to evaluate NEObody™ product candidate, ADG116, and SAFEbody™ product candidate, ADG126, in combination with KEYTRUDA® (pembrolizumab) for patients with advanced/metastatic s...
Adagene Announces Authorization of Share Repurchase Program up to US$20 Million
SAN FRANCISCO and SUZHOU, China, July 07, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the disc...
Adagene Announces Inclusion in FTSE Russell Indexes
SAN FRANCISCO and SUZHOU, China, June 16, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the dis...
Adagene to Present at Upcoming Investor Conferences
SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming t...
Adagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual ...
-Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement